Table 2 Factors associated with survival by univariate analysis.

Sex (male)

1.16 (0.72–1.87)

0.53

1.006 (0.66–1.53)

0.98

Age

1.03 (1.006–1.056)

0.02

1.019 (0.998–1.041)

0.07

PS 2–4

2.69 (1.66–4.35)

< 0.001

2.42 (1.57–3.72)

< 0.001

B symptoms

1.71 (1.022–2.86)

0.04

1.55 (0.98–2.45)

0.06

Serum albumin

0.41 (0.28–0.56)

< 0.001

0.49 (0.35–0.68)

< 0.001

Elevated LDH (> ULN)

2.10 (1.10–4.00)

0.02

2.12 (1.42–4.81)

0.002

Ann-Arbor stage III-IV

2.81 (1.53–5.15)

< 0.001

3.2 (1.83–5.6)

< 0.001

Extranodal lesions

2.24 (1.26–3.97)

0.006

2.49 (1.48–4.19)

< 0.001

Bulky lesion

1.009 (0.54–1.88)

0.98

0.96 (0.55–1.68)

0.89

IPI score

1.50 (1.25–1.79)

< 0.001

1.53 (1.30–1.80)

< 0.001

Diagnosed in other facilities

1.15 (0.61–2.14)

0.67

1.007 (0.57–1.79)

0.98

CHOP (vs dose-reduced)

0.55 (0.34–0.89)

0.02

0.80 (0.53–1.22)

0.31

Nonuse of rituximab

3.76 (1.86–7.58)

< 0.001

2.95 (1.36–6.41)

0.006

Short DTI (0–22 days)

2.89 (1.73–4.83)

< 0.001

2.64 (1.68–4.15)

< 0.001